StreetInsider.com News Articles

CEL-SCI shares Phase 3 Multikine data showing 73% survival rate

Mon, 26 Oct 2026 08:00:28 -0400

CEL-SCI Corporation (NYSE American: CVM) presented new data from its completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection) at the 6th World Congress on Otology, Rhinology and Laryngology in Rome, Italy, according to a company press release.

Chief Scientific Officer Dr. Eyal Talor delivered the keynote address, presenting findings on pre-surgical biomarker identification in head and neck cancer patients. The analysis focused on a subgroup of 114 patients selected using two pre-treatment criteria: locally advanced tumors with no lymph node involvement (N0 status) and low or zero tumor PD-L1 expression, defined as a Tumor Proportion Score below 10%.

In this biomarker-selected

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

Mon, 26 Oct 2026 08:00:00 -0400

Target Population Selection: Biomarker profile – applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS <10%) or zero identifies patients deriving maximum survival benefit from pre-surgical Multikine® treatment.
Nearly 3x Higher Pre-Surgical Response: New analysis demonstrated a statistically significant increase in pre-surgical response/disease downstaging (38% for Multikine + SOC vs. 13% for SOC alone; p = 0.003).
Tumor responses: Significant number of complete and partial tumor responses before surgery.
Substantial Overall Survival Advantage: Biomarker-selected target population demonstrated a 73.4% 5-year survival rate for Multikine-treatment regimen + SOC versus 45.0% for SOC

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

Mon, 26 Oct 2026 08:00:00 -0400

Target Population Selection: Biomarker profile – applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS <10%) or zero identifies patients deriving maximum survival benefit from pre-surgical Multikine® treatment.
Nearly 3x Higher Pre-Surgical Response: New analysis demonstrated a statistically significant increase in pre-surgical response/disease downstaging (38% for Multikine + SOC vs. 13% for SOC alone; p = 0.003).
Tumor responses: Significant number of complete and partial tumor responses before surgery.
Substantial Overall Survival Advantage: Biomarker-selected target population demonstrated a 73.4% 5-year survival rate for Multikine-treatment regimen + SOC versus 45.0% for SOC

Form 4 CEL SCI CORP For: Sep 30 Filed by: TALOR EYAL

Thu, 01 Oct 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20261001/27132311.html

Form 4 CEL SCI CORP For: Sep 30 Filed by: PRICHEP PATRICIA B

Thu, 01 Oct 2026 08:48:00 -0400

si-local-file:///var/storage/secattach/20261001/27132292.html

Form 4 CEL SCI CORP For: Sep 30 Filed by: KERSTEN GEERT R

Thu, 01 Oct 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20261001/27132259.html

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

Tue, 15 Sep 2026 08:37:00 -0400

Keynote presentation at leading head and neck cancer conference will include new findings from CEL-SCI’s landmark Phase 3 study, the largest in the world for its indication
CEL-SCI’s patient selection method is a potential breakthrough advancement in head and neck cancer diagnosis and treatment
Biomarker-based patient selection strategy is being used prospectively in CEL-SCI’s upcoming 212-patient U.S. Confirmatory Registration Study

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced that the Company’s Chief Scientific Officer, Dr. Eyal Talor, has been invited to deliver a keynote presentation at the 6th World Congress on Otology, Rhinology

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

Tue, 15 Sep 2026 08:37:00 -0400

Keynote presentation at leading head and neck cancer conference will include new findings from CEL-SCI’s landmark Phase 3 study, the largest in the world for its indication
CEL-SCI’s patient selection method is a potential breakthrough advancement in head and neck cancer diagnosis and treatment
Biomarker-based patient selection strategy is being used prospectively in CEL-SCI’s upcoming 212-patient U.S. Confirmatory Registration Study

Form S-8 CEL SCI CORP

Thu, 03 Sep 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260903/27025741.html

Form 4 CEL SCI CORP For: Aug 25 Filed by: KERSTEN GEERT R

Wed, 26 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260826/26977795.html

Form 4 CEL SCI CORP For: Aug 25 Filed by: KERSTEN GEERT R

Wed, 26 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260826/26977795.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: Watson Robert Eugene

Mon, 17 Aug 2026 09:43:00 -0400

si-local-file:///var/storage/secattach/20260817/26935988.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: Watson Robert Eugene

Mon, 17 Aug 2026 09:43:00 -0400

si-local-file:///var/storage/secattach/20260817/26935988.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: BAILLAVOINE BRUNO JEAN-MARIE

Mon, 17 Aug 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26935960.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: BAILLAVOINE BRUNO JEAN-MARIE

Mon, 17 Aug 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26935960.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: CIPRIANO JOHN

Mon, 17 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26935942.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: CIPRIANO JOHN

Mon, 17 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26935942.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: TALOR EYAL

Mon, 17 Aug 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260817/26935901.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: TALOR EYAL

Mon, 17 Aug 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260817/26935901.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: PRICHEP PATRICIA B

Mon, 17 Aug 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26935884.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: PRICHEP PATRICIA B

Mon, 17 Aug 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26935884.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: KERSTEN GEERT R

Mon, 17 Aug 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260817/26935865.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: KERSTEN GEERT R

Mon, 17 Aug 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260817/26935865.html

Form 8-K CEL SCI CORP For: Aug 14

Mon, 17 Aug 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935774.html

Form 8-K CEL SCI CORP For: Aug 14

Mon, 17 Aug 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935774.html